Semaglutide for pulmonary disease, chronic obstructive

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Feb 2023: Trial registered, NCT05746039
  2. 29 Jan 2024: Trial started, NCT05746039

The trials

NCT05746039: Feasibility of Semaglutide in Advanced Lung Disease

State
Under way
Phase
Phase 1 and Phase 2
People
8 planned
Started
29 Jan 2024
Primary completion
28 Dec 2027
Arms
Study Drug (semaglutide)
Results
None posted
  1. 27 Feb 2023: Trial registered
  2. 29 Jan 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Arm 2 - DehydraTECH-semaglutide alone, Ozempic, Rybelsus, Semaglutide (Wegovy®), Semaglutide 1.0 mg, Semaglutide 2.4 mg, Semaglutide Injectable Product, Semaglutide Injectable Product (Wegovy and/or Ozempic), Semaglutide Pen Injector, Semaglutide, 1.34 mg/mL, Wegovy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.